The stock of Cyclacel Pharmaceuticals Inc (CYCC) has gone up by 8.42% for the week, with a -73.80% drop in the past month and a -92.09% drop in the past quarter. The volatility ratio for the week is 5.08%, and the volatility levels for the past 30 days are 24.03% for CYCC. The simple moving average for the past 20 days is -48.84% for CYCC’s stock, with a -94.36% simple moving average for the past 200 days.
Is It Worth Investing in Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) Right Now?
Company’s 36-month beta value is 0.15.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for CYCC is 22.27M, and currently, short sellers hold a 0.14% ratio of that floaft. The average trading volume of CYCC on June 25, 2025 was 1.35M shares.
CYCC) stock’s latest price update
Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) has experienced a rise in its stock price by 8.54 compared to its previous closing price of 0.35. However, the company has seen a gain of 8.42% in its stock price over the last five trading days. globenewswire.com reported 2025-06-20 that KUALA LUMPUR, June 20, 2025 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (“Cyclacel”) (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicine, today announced that it has entered into a securities purchase agreement for the sale of its convertible Series F Preferred Stock (“Preferred Stock”) in a private placement to certain accredited investors yielding gross proceeds of $3.0 million before deducting offering expenses. In connection with the offering, Cyclacel issued to each investor, a series A common stock purchase warrant to purchase 3,270,000 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”) at an exercise price of $0.51 per share, series B common stock purchase warrant to purchase 3,270,000 shares of Common Stock at an exercise price of $0.60 per share and series C common stock purchase warrant to purchase 3,270,000 shares of Common Stock at an exercise price of $0.68 per share (collectively, the “Warrants”).
Analysts’ Opinion of CYCC
Many brokerage firms have already submitted their reports for CYCC stocks, with Oppenheimer repeating the rating for CYCC by listing it as a “Outperform.” The predicted price for CYCC in the upcoming period, according to Oppenheimer is $17 based on the research report published on July 18, 2022 of the previous year 2022.
ROTH Capital, on the other hand, stated in their research note that they expect to see CYCC reach a price target of $24. The rating they have provided for CYCC stocks is “Buy” according to the report published on April 27th, 2020.
CYCC Trading at -83.70% from the 50-Day Moving Average
After a stumble in the market that brought CYCC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.05% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CYCC starting from Lazar David E., who sale 194,628,820 shares at the price of $0.03 back on Feb 26 ’25. After this action, Lazar David E. now owns 0 shares of Cyclacel Pharmaceuticals Inc, valued at $5,507,996 using the latest closing price.
Stock Fundamentals for CYCC
Current profitability levels for the company are sitting at:
- 604.05 for the present operating margin
- 1.29 for the gross margin
The net margin for Cyclacel Pharmaceuticals Inc stands at 397.48. The total capital return value is set at -4.13. Equity return is now at value -1949.77, with -168.60 for asset returns.
Based on Cyclacel Pharmaceuticals Inc (CYCC), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -834.47. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -453.04.
Currently, EBITDA for the company is -12.0 million with net debt to EBITDA at 0.27. When we switch over and look at the enterprise to sales, we see a ratio of -225.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.60.
Conclusion
In a nutshell, Cyclacel Pharmaceuticals Inc (CYCC) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
